Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Retinal Vein Occlusion Treatment Market by Treatment Type (Anti-VEGF Injection, Corticosteroid Treatment, Laser Therapy), Age Group (40-60, Above 60, Below 40), Condition Type, End User - Global Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering.

The Retinal Vein Occlusion Treatment Market grew from USD 2.74 billion in 2023 to USD 2.91 billion in 2024. It is expected to continue growing at a CAGR of 6.41%, reaching USD 4.23 billion by 2030.

Key growth factors influencing the RVO treatment market include an aging global population, increasing prevalence of diabetes and hypertension, and advancements in medical technology improving treatment efficacy. Potential opportunities lie in the development of novel therapeutics, particularly biologics and gene therapies, that offer longer-lasting effects or fewer side effects.

While these opportunities are promising, the market faces limitations such as high costs of treatment, limited patient awareness, and complexities associated with chronic management of underlying conditions like diabetes. Additionally, regulatory challenges and long development timelines for new drugs pose significant barriers. Key recommendations for stakeholders include investing in patient education programs to enhance awareness and adherence, collaborations to accelerate innovation in treatment modalities, and expansion into emerging markets with growing healthcare infrastructure.

Areas ripe for innovation include personalized medicine approaches, advances in drug delivery systems, and integration of AI in diagnostic and monitoring tools to enhance treatment precision. The market is characterized by rapid technological development, intense competition among pharmaceutical companies, and a strong focus on research and development aimed at addressing unmet medical needs. With strategic focus on these factors, there is considerable potential for businesses to establish a competitive edge and address the growing demand for effective RVO treatments.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Retinal Vein Occlusion Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

• Growing prevalence of risk factors such as diabetes and hypertension necessitating effective therapies
• Rising healthcare expenditure encouraging investment in retinal vein occlusion treatment options

Market Restraints

• High cost associated with retinal vein occlusion treatment & limited reimbursement policies

Market Opportunities

• Ongoing advances in gene therapy techniques for long-term management of retinal vein occlusion
• Adoption of artificial intelligence in early detection and personalized treatment plans for retinal vein occlusion

Market Challenges

• Comorbidities complication in patient management for retinal vein occlusion treatment

Market Segmentation Analysis

• Treatment Type: Wide adoption of anti-VEGF injections to manage macular edema

Recent Developments

European Commission approves groundbreaking Vabysmo treatment, revolutionizing retinal vein occlusion care across the EU

• The European Commission's approval of Vabysmo marks a significant development in treating visual impairment due to macular edema from retinal vein occlusion (RVO). This approval introduces the first bispecific antibody for RVO, offering a novel treatment since 2015. Vabysmo's primary advantage lies in potentially extending treatment intervals to up to four months, reducing patient burden and healthcare demands. Backed by positive phase 3 studies, Vabysmo achieves non-inferior visual acuity gains compared to aflibercept.

Health Canada approves Vabysmo for retinal vein occlusion

• Health Canada has authorized Vabysmo (faricimab injection) for treating macular edema due to retinal vein occlusion (RVO), marking its third indication following neovascular age-related macular degeneration and diabetic macular edema. This approval is based on two Phase III studies showing early, sustained vision improvements with Vabysmo, comparable to aflibercept, alongside rapid retinal fluid drying. Roche Canada's strategy focuses on expanding Vabysmo's access in Canada and globally, supported by its bispecific action on VEGF-A and Ang-2, aiming to alleviate treatment burdens and enhance patient outcomes over time.

Chugai's Vabysmo secures approval as the first bispecific antibody for retinal vein occlusion treatment in Japan

• Chugai Pharmaceutical has received approval in Japan for Vabysmo, the first bispecific antibody for treating macular edema due to retinal vein occlusion (RVO). This approval stems from successful global phase III trials (BALATON and COMINO) demonstrating Vabysmo's efficacy in enhancing vision and reducing retinal fluid. Vabysmo, innovatively targeting Ang-2 and VEGF-A pathways, stabilizes blood vessels and addresses RVO's severe vision loss risk.

Key Company Profiles

The report delves into recent significant developments in the Retinal Vein Occlusion Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Alimera Sciences, Inc., Bayer AG, Bristol-Myers Squibb Company, Carl Zeiss AG, Fovea Pharmaceuticals SA, Genentech, Inc., GlaxoSmithKline plc, IRIDEX Corporation, Johnson & Johnson Services, Inc., Lumenis Ltd., Novartis AG, Pfizer Inc., Ranbaxy Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Suzuken Co. and Teva Pharmaceutical Industries Ltd.

The report addresses key questions to assist stakeholders in making informed decisions:

• What is the current market size and projected growth?
• Which products, segments, applications, and regions offer promising investment opportunities?
• What are the prevailing technology trends and regulatory frameworks?
• What is the market share and positioning of the leading vendors?
• What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Key Attributes:

Key Topics Covered:

Market Dynamics

• Drivers
  • Growing prevalence of risk factors such as diabetes and hypertension necessitating effective therapies
  • Rising healthcare expenditure encouraging investment in retinal vein occlusion treatment options
• Restraints
  • High cost associated with retinal vein occlusion treatment & limited reimbursement policies
• Opportunities
  • Ongoing advances in gene therapy techniques for long-term management of retinal vein occlusion
  • Adoption of artificial intelligence in early detection and personalized treatment plans for retinal vein occlusion
• Challenges
  • Comorbidities complication in patient management for retinal vein occlusion treatment

Market Segmentation Analysis

• Treatment Type: Wide adoption of anti-VEGF injections to manage macular edema
• Condition Type: Growing prevalence of branch retinal vein occlusion boosting demand for advanced treatments
• Porter's Five Forces Analysis
• PESTLE Analysis

Retinal Vein Occlusion Treatment Market, by Treatment Type

• Anti-VEGF Injection
• Aflibercept
• Bevacizumab
• Ranibizumab
• Corticosteroid Treatment
• Laser Therapy

Retinal Vein Occlusion Treatment Market, by Age Group

• 40-60
• Above 60
• Below 40

Retinal Vein Occlusion Treatment Market, by Condition Type

• Branch Retinal Vein Occlusion
• Central Retinal Vein Occlusion

Retinal Vein Occlusion Treatment Market, by End User

• Ambulatory Surgical Centers (ASCs)
• Hospitals
• Specialty Clinics

Americas Retinal Vein Occlusion Treatment Market

Asia-Pacific Retinal Vein Occlusion Treatment Market

Europe, Middle East & Africa Retinal Vein Occlusion Treatment Market

Competitive Landscape

• Market Share Analysis, 2023
• FPNV Positioning Matrix, 2023

Competitive Scenario Analysis

• European Commission approves ground breaking Vabysmo treatment, revolutionizing retinal vein occlusion care across the EU
• Health Canada approves Vabysmo for retinal vein occlusion
• Chugai's Vabysmo secures approval as the first bispecific antibody for retinal vein occlusion treatment in Japan

Strategy Analysis & Recommendation

Companies Featured

• AbbVie
• Alimera Sciences Inc.
• Bayer AG
• Bristol-Myers Squibb Company
• Carl Zeiss AG
• Fovea Pharmaceuticals SA
• Genentech Inc.
• GlaxoSmithKline plc
• IRIDEX Corporation
• Johnson & Johnson Services Inc.
• Lumenis Ltd.
• Novartis AG
• Pfizer Inc.
• Ranbaxy Pharmaceuticals Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Suzuken Co. Ltd.
• Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/qc24p7

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.